Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Capricor Therapeutics Q3 2026 Results: Net Loss of $42.7M, Loss Widens

Capricor Therapeutics reported total assets of $330.4 million as of September 30, 2026, a decrease from $355.9 million at year-end 2025. The company is currently managing regulatory reviews for its lead product candidate, Deramiocel, while navigating legal disputes with Nippon Shinyaku and Mesoblast International.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-42.7-24.6
Net income-42.7-24.6
EPS (diluted, $ a share)$-0.73$-0.54

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CAPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Capricor Therapeutics, Inc.: key numbers

Share price
$8.30Close, Nov 16
Market cap
$483M
Shares outstanding
58.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Capricor Therapeutics, Inc.

All →
4:06 PM ET 8-K
Financial Results

Capricor Therapeutics Financial Results

Capricor Therapeutics reported Q3 2026 financial results and provided a regulatory update on its BLA for Deramiocel in Duchenne muscular dystrophy, which has a PDUFA date of November 22, 2026. The company ended the quarter with approximately $199 million in cash and marketable securities. Management highlighted clinical data showing a 76% slowing of upper limb decline in patients who switched to Deramiocel during the HOPE-3 open-label extension.

Term
Q3 2026

“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer

“As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.